ChatGPT

Perplexity

Gemini

Claude

Grok

Bienvenido a Moderna, estas a un paso de encontrar la última moda en calzado para toda la familia, tendencias urbanas y tecnología deportiva para tus pies. ¿Qué esperas? Descárganos. 

Con Moderna App

SEJA BEM-VINDO!

Este aplicativo reúne as obras didáticas da Moderna, Richmond e Santillana Español.

Aqui, você encontra seus livros digitais interativos repletos de recursos multimídia, como filmes,

Prioritizing patient well-being and developing life-improving medicines while ensuring accessibility to those who need them.

Patient-Centricity

Emphasizing truthfulness, honesty, and strict compliance with all laws, reflected in commitment to quality in research, development, and product delivery.

Integrity

Holding a deep sense of responsibility for each other, patients, the environment, and local communities.

Responsibility

Reimagining how medicines are created through groundbreaking mRNA technology and continuously pushing scientific boundaries.

Innovation

Moderna is a pioneering American biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines. Best known for its COVID-19 vaccine Spikevax, Moderna is advancing a broad pipeline of mRNA medicines across infectious diseases, oncology, rare diseases, and autoimmune conditions.

Moderna mRNA sequence released to GitHub [pdf]

Moderna’s HIV vaccine has officially begun human trials

Moderna Is About to Begin Trials for HIV Vaccine

Moderna Covid vaccine candidate almost 95% effective, trials show

Moderna's Covid vaccine shows nearly 95% protection

Stéphane Bancel

Chief Executive Officer and Board Member

James Mock

Chief Financial Officer

Stephen Hoge

President

Brad Miller

Chief Information Officer

Jared Collins

Chief Technical Operations and Quality Officer

Shannon Thyme Klinger

Chief Legal Officer and Corporate Secretary

Kate Cronin

Chief Brand Officer

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Moderna reported full-year 2024 revenue of $3.24 billion and provided 2025 guidance of $1.5-2.5 billion. The company announced accelerated cost reduction programs projecting $1.0 billion in savings for 2025 and outlined plans to deliver up to 10 product approvals through 2027.

Moderna Reports Q4 2024 Results, Provides 2025 Guidance

Moderna announced expansion of U.S. manufacturing capabilities with onshoring of drug product manufacturing to its Technology Center in Norwood, Massachusetts. The facility will enable full end-to-end mRNA medicine manufacturing in the U.S., with completion targeted for first half of 2027.

Moderna Expands U.S. Manufacturing with Drug Product Onshoring

Moderna obtained a $1.5 billion loan from Ares Management Credit Funds and outlined a three-year business strategy targeting break-even by 2028. The company also lowered its 2025 sales forecast by $1 billion, citing weak demand for COVID-19 vaccines.

Moderna Secures $1.5B Loan as It Targets Break-Even by 2028

The FDA approved Moderna's updated COVID-19 vaccines, Spikevax and mNEXSPIKE, targeting the LP.8.1 variant for the 2025-2026 respiratory season. The approval provides updated protection against currently circulating SARS-CoV-2 strains.

FDA Approves Moderna's Updated COVID-19 Vaccines for 2025-2026 Season

GSK plc filed a lawsuit in Delaware seeking unspecified royalties, alleging that Moderna's COVID-19 vaccine and RSV vaccine mRESVIA infringe on GSK's patents related to lipid nanoparticle technology used in mRNA delivery systems.

GSK Files Patent Lawsuit Against Moderna Over mRNA Technology

Moderna revealed plans to reduce annual R&D expenses from $4.8 billion in 2024 to $3.6-3.8 billion by 2027. The company will discontinue five clinical programs to focus resources on high-priority pipeline assets including flu/COVID combination vaccine and cancer programs.

Moderna Announces R&D Restructuring, Discontinues Five Programs

The FDA approved mRESVIA (mRNA-1345), Moderna's RSV vaccine for adults 60 and older, marking the company's second approved product and the world's first mRNA-based RSV vaccine. The approval represents a significant pipeline diversification milestone beyond COVID-19.

FDA Approves mRESVIA, Moderna's RSV Vaccine for Older Adults

Moderna says FDA refuses to review its application for experimental flu shot

Moderna Inc.'s CEO said the company doesn't plan to invest in new late-stage vaccine trials due to growing opposition to immunizations from US officials

Moderna Glassdoor Review

Moderna is in a generational Yolo territory

Moderna: Now With 500 Fewer Employees, But Hey… Promotions!

mRNA cancer vaccines are showing real results — Moderna/Merck's melanoma vaccine cut death and recurrence risk by 50% over 5 years, with trials now expanding to breast, pancreatic, and lung cancers

How Moderna, the company that helped save the world, unraveled

HIV contamination found in Moderna's Covid Vaccine

Offer from moderna

Possibility of Moderna layoff because of mrna-1010 RTF/Trump administration chaos???

biotech

news

technology

wallstreetbets

unvaccinated

ModernaStock

Moderna, Inc.

Biological Products, (No Diagnostic Substances)

Moderna (ModeRNA Therapeutics) was founded in Cambridge, Massachusetts by Derrick Rossi, Robert Langer, Kenneth R. Chien, Timothy A. Springer, and Noubar Afeyan with backing from Flagship Pioneering to commercialize mRNA technology.

Company Founded

Stéphane Bancel joined Moderna as the founding CEO, bringing operational expertise and business acumen to complement the scientific vision of the founders.

Stéphane Bancel Appointed CEO

Moderna formed a strategic partnership with AstraZeneca to develop mRNA treatments for cardiovascular, metabolic, and renal diseases, as well as cancer, validating the platform's potential.

AstraZeneca Partnership

The company entered an agreement with Alexion Pharmaceuticals to develop mRNA treatments against ten rare diseases, expanding its therapeutic pipeline.

Alexion Pharmaceuticals Agreement

Moderna developed its first mRNA vaccine candidate targeting influenza, demonstrating the versatility of the mRNA platform for infectious disease prevention.

First Influenza mRNA Vaccine

Moderna completed its initial public offering, raising $604 million in one of the largest biotech IPOs in history, providing capital to advance its mRNA pipeline.

Record-Breaking IPO

Moderna announced development of mRNA-1273, an mRNA vaccine to induce immunity to SARS-CoV-2, with support from $2.5 billion in U.S. government funding through BARDA.

COVID-19 Vaccine Development Begins

The FDA granted Emergency Use Authorization for mRNA-1273 (Spikevax), Moderna's COVID-19 vaccine, propelling the company to global prominence and validating the mRNA platform.

COVID-19 Vaccine Emergency Use Authorization

Moderna announced plans to build a $180 million vaccine manufacturing facility in Montreal, Canada, in partnership with the Government of Canada, Quebec, and McGill University.

Montreal Manufacturing Facility Announced

Moderna completed its first acquisition, purchasing OriCiro Genomics, a Japanese manufacturer of genetic engineering tools, to enhance its technology capabilities.

First Acquisition: OriCiro Genomics

The FDA approved mRESVIA, Moderna's mRNA respiratory syncytial virus vaccine for adults 60 and older, marking the company's second approved product and the world's first mRNA RSV vaccine.

RSV Vaccine Approval

Moderna announced plans to reduce annual R&D expenses from $4.8 billion in 2024 to $3.6-3.8 billion by 2027, discontinuing five clinical programs to focus on high-priority pipeline assets.

R&D Cost Reduction Strategy

GSK plc filed a lawsuit in Delaware against Moderna seeking royalties, alleging that Moderna's COVID-19 and RSV vaccines infringe on GSK's lipid nanoparticle patents.

GSK Patent Lawsuit

Moderna secured a $1.5 billion loan from Ares Management Credit Funds and outlined a three-year strategy targeting break-even by 2028 with $1.5 billion in total cost savings.

Strategic Restructuring and Financing

Moderna announced expansion of U.S. manufacturing with onshoring of drug product capabilities at its Technology Center in Norwood, Massachusetts, targeting completion by 2027.

U.S. Manufacturing Expansion

Turn your phone into a powerful payment terminal. Accept donations, sell tickets and track all payments instantly — no extra hardware needed!

With the Zeffy app, your nonprofit can:
• Accept all majo

Moderna vs Zeffy

Moderna

About

Zeffy

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time